AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

AstraZeneca has announced a landmark agreement with President Donald J. Trump’s administration aimed at significantly reducing prescription medicine costs for American patients while simultaneously bolstering the nation’s biopharmaceutical innovation and manufacturing capabilities. The announcement was made at a White House event where AstraZeneca CEO Pascal Soriot joined President Trump and senior officials.

The agreement confirms AstraZeneca’s voluntary compliance with all four requests outlined in the President’s July 31 letter, promising to align U.S. drug prices with those in other wealthy nations under a “most-favored-nation” (MFN) pricing model.

Key Pillars of the Agreement

Lower Drug Prices for Patients:
- Direct-to-Consumer (DTC) Sales: Eligible patients with prescriptions for chronic diseases can access AstraZeneca medicines at discounts of up to 80% off list prices.
- TrumpRx.gov Platform: AstraZeneca will participate in this platform, allowing patients to purchase medicines directly from the company at reduced cash prices.
- Medicaid Savings: Every state Medicaid program will gain access to MFN drug prices on AstraZeneca products, projected to generate hundreds of millions in savings.
- Specific Drug Reductions: Approximately 9 million American patients will benefit. For example, AstraZeneca’s BEVESPI AEROSPHERE (COPD) will see a discount equal to 654% of the deal price, BREZTRI AEROSPHERE (COPD) at 98%, and AIRSUPRA (asthma) at 96%.
Massive Investment in U.S. Manufacturing and R&D:
- $50 Billion Investment: AstraZeneca commits to investing $50 billion in U.S. manufacturing and R&D over the next five years (by 2030).
- Domestic Production: All medicines sold in the United States will be produced domestically, supported by a three-year delay on Section 232 tariffs from the U.S. Department of Commerce to facilitate full onshoring of manufacturing.
- New Facilities:
  - Groundbreaking on the largest manufacturing facility to date in Virginia (supporting weight management, metabolic portfolio, and antibody-drug conjugate cancer pipeline, creating 3,600 skilled jobs).
  - Expanded facility in Coppell, Texas (opening next week).
  - New cell therapy manufacturing facility in Rockville, Maryland (early next year).
  - Second major R&D center in Cambridge, Massachusetts (opening late 2026).

Statements and Broader Impact

Pascal Soriot, AstraZeneca CEO, emphasized that the agreement will enable millions of Americans to access “life-changing medicines at lower prices” while safeguarding “America’s pioneering role as a global powerhouse in innovation.” He also called on other wealthy nations to “step up their contribution to fund innovation.”

President Trump hailed this as the second such agreement with a major pharmaceutical company under his administration’s “most-favored-nation” pricing model. He asserted that the deal ends global freeloading on American pharmaceutical innovation, pointing out that Americans currently pay significantly more for brand-name drugs compared to other developed nations, effectively subsidizing global socialism.

The agreement aligns with President Trump’s May 12, 2025, Executive Order “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” reinforcing his administration’s commitment to prioritizing American patients and bringing drug prices in line with international levels.